{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.2","value":"4.5"},{"groupId":"OG001","spread":"2.5","value":"4.0"},{"groupId":"OG002","spread":"2.3","value":"4.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"221"},{"groupId":"OG001","value":"223"},{"groupId":"OG002","value":"222"}],"units":"Participants"}],"description":"Participants rated their tiredness by selecting a number from 0 to 10 that best described their level of worst tiredness during the past 24 hours, where 0 represents \"no tiredness\" and 10 represents \"as bad as you can imagine\". Participants reported their worst tiredness in daily electronic diaries. The average value across the 7 days preceding each visit is calculated. A decrease in tiredness severity rating indicated an improvement in the participant's condition.","dispersionType":"Standard Deviation","groups":[{"description":"Placebo administered orally once daily through Week 24.\n\nParticipants continued to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study.","id":"OG000","title":"Placebo"},{"description":"Baricitinib 2 mg administered orally once daily through Week 24.\n\nParticipants continued to take background cDMARD therapy throughout study.","id":"OG001","title":"Baricitinib 2 mg"},{"description":"Baricitinib 4 mg administered orally once daily through Week 24.\n\nParticipants continued to take background cDMARD therapy throughout study.","id":"OG002","title":"Baricitinib 4 mg"}],"paramType":"MEAN","populationDescription":"mITT population: all randomized participants who received at least 1 dose of the study drug and had at least 4 entries within any post-baseline 7-day window are included in the analysis.","reportingStatus":"POSTED","timeFrame":"Week 12","title":"Mean Worst Tiredness Numeric Rating Scale (NRS) in the Prior 7 Days as Collected in Electronic Diaries","type":"SECONDARY","unitOfMeasure":"units on a scale"}